Expression of c-MET in Invasive Meningioma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Meningiomas show high recurrence rates even after curative tumor removal. The invasiveness of meningiomas may contribute to their high recurrence rates. Recently, c-MET and hepatocyte growth factor (HGF) have been reported to be involved in cancer invasion. Methods: We examined the immunohistochemical expression of c-MET and HGF in 100 cases of patientswith meningiomas who have undergone complete tumor removal. Results: c-MET-High and HGFHigh were found in 17% and 13% of meningiomas, respectively. Brain invasion was observed in 17.6% of c-MET-High meningiomas, but in only 2.4% of c-MET-Low meningiomas (p=.033). Bone/soft tissue invasion was observed in 23.5% of c-MET-High meningiomas and in 9.6% of c-MET-Lowmeningiomas (p=.119). HGF-High did not show statistical association with brain invasion or bone/soft tissue invasion. c-MET-High demonstrated shorter recurrence-free survival (RFS, 93.5±8.2 months vs 96.1±1.9 months); however, this difference was not statistically significant (p=.139). There was no association of HGF-High with RFS. Conclusions: This study demonstrates that c-MET-High is associated with brain invasion of meningiomas, and that c-MET expression may be a useful predictive marker for meningioma recurrence. Patients with invasive meningiomas with high expressions of c-MET may be good candidates for targeted therapy using c-MET inhibitors.
Abstract
Background: Meningiomas show high recurrence rates even after curative tumor removal. The invasiveness of meningiomas may contribute to their high recurrence rates. Recently, c-MET and hepatocyte growth factor (HGF) have been reported to be involved in cancer invasion. Methods: We examined the immunohistochemical expression of c-MET and HGF in 100 cases of patientswith meningiomas who have undergone complete tumor removal. Results: c-MET-High and HGFHigh were found in 17% and 13% of meningiomas, respectively. Brain invasion was observed in 17.6% of c-MET-High meningiomas, but in only 2.4% of c-MET-Low meningiomas (p=.033). Bone/soft tissue invasion was observed in 23.5% of c-MET-High meningiomas and in 9.6% of c-MET-Lowmeningiomas (p=.119). HGF-High did not show statistical association with brain invasion or bone/soft tissue invasion. c-MET-High demonstrated shorter recurrence-free survival (RFS, 93.5±8.2 months vs 96.1±1.9 months); however, this difference was not statistically significant (p=.139). There was no association of HGF-High with RFS. Conclusions: This study demonstrates that c-MET-High is associated with brain invasion of meningiomas, and that c-MET expression may be a useful predictive marker for meningioma recurrence. Patients with invasive meningiomas with high expressions of c-MET may be good candidates for targeted therapy using c-MET inhibitors.
참고문헌 (30)
- Louis DN, "WHO classification of tumours of the central nervous system" (2007), IARC Press
- Choy W, "The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments", Neurosurg Focus, 30, pp.E6~ (2011)
- Karja V, "Does protein expression predict recurrence of benign World Health Organization grade I meningioma?", Hum Pathol, 41, pp.199~207 (2010)
- Perry A, "Meningioma grading: an analysis of histologic parameters", Am J Surg Pathol, 21, pp.1455~1465 (1997)
- Ildan F, "Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up", Skull Base, 17, pp.157~171 (2007)
- Durand A, "WHO grade II and III meningiomas : a study of prognostic factors", J Neurooncol, 95, pp.367~375 (2009)
- Caltabiano R, "Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas : an immunohistochemical and fluorescence in situ hybridization pilot study", J Neurosurg Sci, 57, pp.139~151 (2013)
- Barresi V, "MMP-9 expression in meningiomas: a prognostic marker for recurrence risk?", J Neurooncol, 102, pp.189~196 (2011)
- Fathi AR, "Meningioma", Curr Neurol Neurosci Rep, 13, pp.337~ (2013)
- Alahmadi H, "Pathology and genetics of meningiomas", Semin Diagn Pathol, 28, pp.314~324 (2011)
- Terzi A, "The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays", Pathol Res Pract, 204, pp.305~314 (2008)
- Kliese N, "miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells", Oncogene, 32, pp.4712~4720 (2013)
- Liu X, "Developing c-MET pathway inhibitors for cancer therapy: progress and challenges", Trends Mol Med, 16, pp.37~45 (2010)
- Guessous F, "An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth", Anticancer Agents Med Chem, 10, pp.28~35 (2010)
- Organ SL, "An overview of the c-MET signaling pathway", Ther Adv Med Oncol, 3(1 Suppl), pp.S7~S19 (2011)
- Feng Y, "MET signaling: novel targeted inhibition and its clinical development in lung cancer", J Thorac Oncol, 7, pp.459~467 (2012)
- Martínez-Rumayor A, "Coexpression of hepatocyte growth factor", scatter factor(HGF, Cancer Lett, pp.2004, 213[DOI]
- Lamszus K, "Vascular endothelial growth factor, hepatocyte growth factor", scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy, 2000, pp.46, 938~947
- 김나래, "Expression of Hepatocyte Growth Factor", c-met by RT-PCR in Meningiomas, 2011, pp.45(5), 463~468[DOI]
- 서자희, "ERG Immunohistochemistry and Clinicopathologic Characteristics in Korean Prostate Adenocarcinoma Patients", Journal of Pathology and Translational Medicine, 46(5), pp.423~428 (2012), 대한병리학회[DOI]
- Bozkaya G, "Cooperative interaction of MUC1 with the HGF", c-Met pathway during hepatocarcinogenesis, 2012, pp.11, 64~
- Kong DS, "Prognostic significance of c-Met expression in glioblastomas", Cancer, 115, pp.140~148 (2009)
- Palma L, "Long-term prognosis for atypical and malignant meningiomas : a study of 71 surgical cases", J Neurosurg, 86, pp.793~800 (1997)
- Gabeau-Lacet D, "Bone involvement predicts poor outcome in atypical meningioma", J Neurosurg, 111, pp.464~471 (2009)
- Eder JP, "Novel therapeutic inhibitors of the c-Met signaling pathway in cancer", Clin Cancer Res, 15, pp.2207~2214 (2009)
- Yamasaki F, "Recurrence of meningiomas", Cancer, 89, pp.1102~1110 (2000)
- Violaris K, "The recurrence rate in meningiomas: analysis of tumor location, histological grading, and extent of resection", Open J Mod Neurosurg, 2, pp.6~10 (2011)
- Jääskeläinen J, "Seemingly complete removal of histologically benign intracranial meningioma : late recurrence rate and factors predicting recurrence in 657 patients : a multivariate analysis", Surg Neurol, 26, pp.461~469 (1986)
- Edakuni G, "Expression of the hepatocyte growth factor", c-Met pathway is increased at the cancer front in breast carcinoma, 2001, pp.51, 172~178
- Terada T, "Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis", Hum Pathol, 29, pp.175~180 (1998)